vs
STANDARD BIOTOOLS INC.(LAB)与Workhorse Group Inc.(WKHS)财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Workhorse Group Inc.的1.6倍($19.6M vs $12.5M),Workhorse Group Inc.净利率更高(-166.5% vs -177.4%,领先11.0%),Workhorse Group Inc.同比增速更快(432.0% vs -11.5%),Workhorse Group Inc.自由现金流更多($-11.1M vs $-23.1M),过去两年Workhorse Group Inc.的营收复合增速更高(205.7% vs -12.2%)
Standard BioTools(原Fluidigm公司)是一家美国生命科学工具企业,主营流式细胞术与组织成像分析用质谱流式系统,以及配套的检测试剂盒与试剂,同时供应自动化基因组分析仪器、各类微流控芯片(又称集成流体电路)及配套试剂耗材,全系列产品及应用场景均可提供定制检测方案与相关服务。
沃克斯集团是一家总部位于美国俄亥俄州沙伦维尔的原始设备制造商与科技公司。2025年,该公司与Motiv电动卡车公司完成业务合并,组建了名为Workhorse的全新经营主体。
LAB vs WKHS — 直观对比
营收规模更大
LAB
是对方的1.6倍
$12.5M
营收增速更快
WKHS
高出443.5%
-11.5%
净利率更高
WKHS
高出11.0%
-177.4%
自由现金流更多
WKHS
多$11.9M
$-23.1M
两年增速更快
WKHS
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $19.6M | $12.5M |
| 净利润 | $-34.7M | $-20.8M |
| 毛利率 | 48.5% | 80.4% |
| 营业利润率 | -168.5% | -28.6% |
| 净利率 | -177.4% | -166.5% |
| 营收同比 | -11.5% | 432.0% |
| 净利润同比 | -28.8% | -171.8% |
| 每股收益(稀释后) | $-0.09 | $0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
LAB
WKHS
| Q4 25 | — | $12.5M | ||
| Q3 25 | $19.6M | $2.4M | ||
| Q2 25 | $21.8M | $5.7M | ||
| Q1 25 | $40.8M | $640.9K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $22.1M | $2.5M | ||
| Q2 24 | $22.5M | $842.4K | ||
| Q1 24 | $45.5M | $1.3M |
净利润
LAB
WKHS
| Q4 25 | — | $-20.8M | ||
| Q3 25 | $-34.7M | $-7.8M | ||
| Q2 25 | $-33.5M | $-14.8M | ||
| Q1 25 | $-26.0M | $-20.6M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | $-26.9M | $-25.1M | ||
| Q2 24 | $-45.7M | $-26.3M | ||
| Q1 24 | $-32.2M | $-29.2M |
毛利率
LAB
WKHS
| Q4 25 | — | 80.4% | ||
| Q3 25 | 48.5% | -323.2% | ||
| Q2 25 | 48.8% | -130.2% | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | -164.7% | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率
LAB
WKHS
| Q4 25 | — | -28.6% | ||
| Q3 25 | -168.5% | -694.2% | ||
| Q2 25 | -118.1% | -255.3% | ||
| Q1 25 | -80.8% | -2002.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -120.9% | -564.5% | ||
| Q2 24 | -134.5% | -2435.6% | ||
| Q1 24 | -132.2% | -1771.6% |
净利率
LAB
WKHS
| Q4 25 | — | -166.5% | ||
| Q3 25 | -177.4% | -328.2% | ||
| Q2 25 | -153.7% | -260.7% | ||
| Q1 25 | -63.8% | -3221.0% | ||
| Q4 24 | — | 1233.7% | ||
| Q3 24 | -122.0% | -1001.5% | ||
| Q2 24 | -203.3% | -3124.3% | ||
| Q1 24 | -70.6% | -2177.0% |
每股收益(稀释后)
LAB
WKHS
| Q4 25 | — | $0.09 | ||
| Q3 25 | $-0.09 | $-0.50 | ||
| Q2 25 | $-0.09 | $-1.67 | ||
| Q1 25 | $-0.07 | $-4.68 | ||
| Q4 24 | — | $51.11 | ||
| Q3 24 | $-0.07 | $-0.98 | ||
| Q2 24 | $-0.12 | $-17.45 | ||
| Q1 24 | $-0.27 | $-24.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $12.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $43.0M |
| 总资产 | $539.6M | $117.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
LAB
WKHS
| Q4 25 | — | $12.9M | ||
| Q3 25 | $129.4M | $12.7M | ||
| Q2 25 | $158.6M | $2.2M | ||
| Q1 25 | $150.9M | $2.6M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | $210.6M | $3.2M | ||
| Q2 24 | $269.8M | $5.3M | ||
| Q1 24 | $287.1M | $6.7M |
总债务
LAB
WKHS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益
LAB
WKHS
| Q4 25 | — | $43.0M | ||
| Q3 25 | $399.7M | $32.1M | ||
| Q2 25 | $424.5M | $22.3M | ||
| Q1 25 | $454.6M | $31.4M | ||
| Q4 24 | — | $-40.8M | ||
| Q3 24 | $489.3M | $47.3M | ||
| Q2 24 | $510.3M | $58.6M | ||
| Q1 24 | $577.3M | $67.4M |
总资产
LAB
WKHS
| Q4 25 | — | $117.9M | ||
| Q3 25 | $539.6M | $116.7M | ||
| Q2 25 | $557.0M | $99.3M | ||
| Q1 25 | $579.6M | $115.5M | ||
| Q4 24 | — | $37.4M | ||
| Q3 24 | $681.5M | $101.4M | ||
| Q2 24 | $708.7M | $105.4M | ||
| Q1 24 | $777.7M | $113.9M |
负债/权益比
LAB
WKHS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-10.5M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-11.1M |
| 自由现金流率自由现金流/营收 | -118.1% | -89.0% |
| 资本支出强度资本支出/营收 | 4.5% | 4.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势,按日历期对齐
经营现金流
LAB
WKHS
| Q4 25 | — | $-10.5M | ||
| Q3 25 | $-22.2M | — | ||
| Q2 25 | $-20.7M | — | ||
| Q1 25 | $-30.3M | $-8.2M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | $-27.9M | — | ||
| Q2 24 | $-39.0M | $-12.1M | ||
| Q1 24 | $-62.5M | $-18.0M |
自由现金流
LAB
WKHS
| Q4 25 | — | $-11.1M | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | $-8.2M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | $-12.8M | ||
| Q1 24 | $-63.3M | $-21.0M |
自由现金流率
LAB
WKHS
| Q4 25 | — | -89.0% | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | -1275.0% | ||
| Q4 24 | — | 52.2% | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | -1523.4% | ||
| Q1 24 | -138.9% | -1567.2% |
资本支出强度
LAB
WKHS
| Q4 25 | — | 4.8% | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | 2.8% | ||
| Q4 24 | — | 31.2% | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | 87.1% | ||
| Q1 24 | 1.7% | 225.9% |
现金转化率
LAB
WKHS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
WKHS
暂无分部数据